Direct evidence linking hesperidin to meaningful GLP-1 activation in humans is sparse
One key group includes individuals with pernicious anemia, an autoimmune condition that affects the bodys ability to absorb vitamin B12 from food
Some of the more common side effects of GLP-1s are nausea, vomiting, and diarrhea
Therefore, CB-839 has been tested in many clinical trials, including colorectal cancer (NCT02861300), triple-negative breast cancer (NCT02071862), renal cell carcinoma (NCT03163667), melanoma (NCT02771626), and others (Table 2)
Households with at least one GLP-1 user slashed their grocery spending by approximately 6% within six months of starting the medication as they pulled back on calorie-dense processed foods, according to a recent study by Cornell University and Numerator